At SupplySide West 2019, in Las Vegas, NV, DolCas Bioetech LLC (Landing, NJ) is launching Bergacyn, a blend of botanical extracts from Italian bergamot citrus fruit (Citrus bergamia) and the wild-crafted Italian artichoke thistle leaf (Cynara cardunculus sylvestris). The new formulation is solvent-free, as well as USDA and EU certified organic.
“Bergacyn is not simply a blend of two powdered herbs,” said Vincenzo Mollace, PhD, a professor at the University of Catanzaro and a top researcher in the area of nutraceuticals, in a press release. “The synergism activated by the patented, in-process combination reduces the clinically substantiated, individual dose requirements of Bergamot and Cynara — at 1,300 mg and 500 mg, respectively — to only 300 mg in Bergacyn.”
Independently, bergamot is known for supporting lipid metabolism, overall cardiovascular health, and blood glucose control, while Cynara is known to support liver and cardiometabolic health. Cynara may also have anti-inflammatory mechanisms. The ingredients are also full traceable.
“Bergacyn was designed specifically to accommodate current ingredient trends for better-for-you products, including: clean-label, plant-based, sustainability, and transparency,” explained Shavon Jackson-Michel, ND, director of medical and scientific affairs at DolCas Biotech, in a press release. “Our manufacturers control more than 80% of the raw bergamot fruit material produced in the Reggio Calabria region, as well as exclusively growing and harvesting the Cynara artichoke leaf that goes into Bergacyn. The bergamot compound derived from the fruit — the base ingredient for Bergacyn — is extracted from parts of the fruit left over from its use in the perfume industry, upcycling a powerful product that would normally go to waste.”
Bergacyn’s low-dose format helps improve compliance and cost effectiveness for the end consumer. It’s also suitable for multiple applications including capsules, tablets, and powders for medical foods, shots, and beverages.